目的 探究苏黄止咳胶囊辅助治疗咳嗽变异性哮喘的疗效及安全性。方法 选择2013年2月—2014年12月期间洪泽县人民医院收治的100例咳嗽变异性哮喘患者, 按照随机数字法分为治疗组和对照组, 每组各50例。对照组患者给予常规止咳及对症治疗, 治疗组患者则在对照组基础上服用苏黄止咳胶囊辅助治疗。观察两组临床症状的消失时间及不良反应发生情况。治疗前后采用肺功能仪测定用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、呼气峰值流量(PEF)等肺功能指标。采用酶联免疫吸附法测定血清IL-6、TNF-α水平。采用流式细胞仪检测CD3+、CD4+、CD8+、CD4+/CD8+等细胞免疫指标。结果 治疗后, 治疗组总有效率为94.0%、不良反应发生率为8.0%, 对照组分别为70.0%和50.0%, 差异均有统计学意义(P<0.05)。治疗组咳嗽症状起效时间、气喘及哮鸣音消失时间、咳嗽消失时间明显短于对照组(P<0.05)。治疗前两组肺功能, 血清IL-6、TNF-α水平, CD3+、CD4+、CD4+/CD8+、CD8+等差异均无统计学意义, 治疗后各指标两组组内及组间差异均有统计学意义(P<0.05)。结论 苏黄止咳胶囊辅助治疗咳嗽变异性哮喘患者, 能够明显提高临床疗效, 改善肺功能, 且具有较好的安全性, 其机制可能与提高CD3+、CD4+, 下调CD8+, 减少IL-6、TNF-α促炎症细胞因子分泌, 增强机体细胞免疫功能有关。
Objective To explore the effect and safety of Suhuang Zhike Capsule used in the treatment of cough variant asthma. Methods From February 2013 to December 2014, 100 cases with cough variant asthma in our hospital were selected and divided into treatment group and control group, 50 cases in each group. The patients in the control group were given conventional cough treatment, while the patients in the treatment group were given Suhuang Zhike Capsule. the disappear time of clinical symptoms and adverse reaction between the two groups were observed: The lung function indices such as FVC, FEV1 and PEF were detected by Spiromete; The levels of serum IL-6 and TNF-α were measured by ELISA, and the cellular immunity indexes of CD3+, CD4+, CD8+, and CD4+/CD8+ etc were determined by FACS. Results After the treatment, the total effective rate of the the patients in the treatment group was 94.0%, the incidence of adverse reactions was 8.0%, while the control was 70.0% and 50.0%, respectively, the differences were statistically significant (P < 0.05); The onset time of effect on cough, the disappear time of asthma and wheezing sound, and cough lose time of the patients in the treatment group were significantly shorter than those of the patients in the control group (P < 0.05). Before the treatment, the lung function, serum levels of IL-6 and TNF-a, and CD3+, CD4+, CD8+, C CD4+/D8+, etc in the two groups were no statistically significant difference (P > 0.05). But after the treatment, the differences were no statistically significance in each group. Conclusion Suhuang Zhike Capsule used in the treatment of cough variant asthma can obviously improve the clinical curative effect and lung function and have good security. The mechanism may be related to the increase of CD3+, CD4+, CD8+, decrease of IL-6 and TNF-α secretion, and enhancement of the cellular immune function.